Targeting the KIF4A/AR axis to reverse endocrine therapy resistance in castration-resistant prostate cancer.
Emerging evidence indicates that castration-resistant prostate cancer (CRPC) is often driven by constitutively active androgen receptor (AR) or its V7 splice variant (AR-V7) and commonly becomes resistant to endocrine therapy. The aim of this work is to evaluate the function of a kinesin protein, KIF4A, in regulating AR/AR-V7 in prostate cancer endocrine therapy resistance. We examined KIF4A expression in clinical prostate cancer specimens by immunohistochemistry. Regulated pathways were investigated by qRT-PCR, immunoblot analysis, immunoprecipitation, and luciferase reporter and chromatin immunoprecipitation (ChIP) assays. A series of functional analyses were conducted in cell lines and xenograft models. Examination of the KIF4A protein and mRNA levels in prostate cancer patients showed that increased expression of KIF4A was positively correlated with AR levels. Patients with lower tumor KIF4A expression had improved overall survival (OS) and disease-free survival (DFS). Mechanistically, KIF4A and AR form an auto-regulatory positive feedback loop in prostate cancer: KIF4A binds AR and AR-V7 and prevents CHIP-mediated AR and AR-V7 degradation; AR binds the promoter region of KIF4A and activates its transcription. KIF4A promotes castration-sensitive and castration-resistant prostate cancer cell growth through AR- and AR-V7-dependent signaling. Furthermore, KIF4A expression is upregulated in enzalutamide (ENZ)-resistant prostate cancer cells, and KIF4A knockdown effectively reverses ENZ resistance and enhances the sensitivity of CRPC cells to endocrine therapy. These findings indicate that KIF4A plays an important role in the progression of CRPC and serves as a crucial determinant of the resistance of CRPC to endocrine therapy.